logo-loader
viewA1 Investments & Resources

A1 Investments & Resources inks agriculture deal with Sol Holdings Corporation

au_australian_dollar350_54753db089b77.jpg

A1 Investments & Resources (ASX:AYI) has exchanged a letter of understanding with SOL Holdings Corporation (TYO:6636) to develop the SuperSorghum business by means of an exclusive distribution agreement in favour of A1 for Australia.

A1 intends to complete a series of documents that provide for a long term capital and business alliance with SOL.

Since SOL signed a memorandum of understanding with A1 in March 2014, SOL has made placements in A1 to a sum of $200,000.

In March, A1 entered a heads of agreement to acquire Singapore based Marvel Seeds, a worldwide distributor of Super Sorghum seeds from Japan. Marvel had an existing arrangement with Sol.

Super Sorghum is a fast growing and high yielding crop, extremely drought tolerant and easily convertible to bioethanol.

SOL has confirmed an offer of an exclusive distribution agreement for SuperSorghum in Australia by its subsidiary SOL Asia, to A1 for a term of 5 years for an exclusivity payment of $500,000.

A1 is in the process of sourcing funding to pay this fee.

SOL has also confirmed its commitment to assist A1 with arranging of the capital funding requirements of such ventures including new plant, stock yards and feed lots as required.

A1 has 6 months to finalise the funding, distribution agreement, and business alliance agreement.

These agreements with a large Japanese listed company could become a profitable partnership for A1.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: A1 Investments & Resources

Price: 0.001 AUD

ASX:AYI
Market: ASX
Market Cap: $24.02 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics' Glyn Edwards talks US$50mln backing and ridinilazole...

Summit Therapeutics PLC's (LON:SUMM, NASDAQ:SMMT) CEO Glyn Edwards sat down with Proactive London's Andrew Scott following the news of a US$50mln funding deal with biotech billionaire Bob Duggan. The investment will help get the company’s next-generation antibiotic through phase III clinical...

9 hours, 18 minutes ago

2 min read